Skip to main content
  • Sign in
  • Help
BOPA
  • Why join BOPA
  • Pricing
  • Education
    • BOPA Introduction to Cancer Course 2025
    • Courses and eLearning
    • SACT Verification Hub (Passport)
    • Resource Library
    • Cancer Hub
    • Education & Training Standards
    • Let’s Talk About SACT – a BOPA Podcast
  • About BOPA
    • About BOPA
    • Welcome to BOPA
    • Executive Committee
    • Subcommittees & working groups
    • Affiliated Groups
    • Specialist Advisory Groups
    • International Groups
    • BOPA Fellows
    • Corporate Membership
    • BOPA membership FAQs
  • Conference
    • Latest Conference 2025
    • Abstract Submission Opens 31st March
    • Past Symposiums / Conferences
  • News & Events
    • News
    • Events calendar
    • Submit event
  • Menu iconLCC
    • LCC
    • Cancer Hub
  • Join BOPA
Join BOPA
BOPA Join BOPA
  • Why join BOPA
  • Pricing
  • Education
    • BOPA Introduction to Cancer Course 2025
    • Courses and eLearning
    • SACT Verification Hub (Passport)
    • Resource Library
    • Cancer Hub
    • Education & Training Standards
    • Let’s Talk About SACT – a BOPA Podcast
  • About BOPA
    • About BOPA
    • Welcome to BOPA
    • Executive Committee
    • Subcommittees & working groups
    • Affiliated Groups
    • Specialist Advisory Groups
    • International Groups
    • BOPA Fellows
    • Corporate Membership
    • BOPA membership FAQs
  • Conference
    • Latest Conference 2025
    • Abstract Submission Opens 31st March
    • Past Symposiums / Conferences
  • News & Events
    • News
    • Events calendar
    • Submit event
  • Menu iconLCC
    • LCC
    • Cancer Hub
  • Join BOPA

Home » Systemic anticancer therapy (SACT)

Systemic anticancer therapy (SACT)

BOPA encourages its members to share helpful documents that can benefit other members.  BOPA respects the intellectual property of original authors and requires anyone who uses other members’ work to include an acknowledgment of, or reference to, the source in their version.

DISCLAIMER:
BOPA is not the author or owner of some of the documents published on our website.  BOPA as a professional interest group will share documents via its website that are of interest to BOPA members, but has no responsibility for use of the documents and for any recommendations within the documents so members must use these at their discretion. BOPA cannot accept responsibility for any errors or omissions or for any consequences from application of information in the documents attached and make no warranty, expressed or implicit with respect to the contents of this webpage. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site or document(s) downloaded from it.

Posters and abstracts on the BOPA website remain the property of the authors and anyone wishing to reference or share this work must contact the authors directly. Abstracts subsequently published in JOPP follow copyright rules from JOPP.

Last reviewed: 12/10/20 by Laura J. Miller

Height and weight reporting frequency for BSA and weight prescribed chemotherapy and its impact on weight change interpretation in an acute hospital? A retrospective audit

Abstracts

View resources
Last reviewed: 27/04/20 by Siobhan Smith

Exploring the feasibility of IGEV delivery through an ambulatory service

View resources
Last reviewed: 27/04/20 by Sandrine von Grünigen

Cyto-SAT: a self-assessment tool for safe handling of cytotoxic medicines in low and middle-income countries

View resources
Last reviewed: 27/04/20 by Takahiro Ohta

Clinical utility of the press through pack seal-type adherence support tool for locally advanced rectal cancer patients receiving capecitabine-based chemoradiotherapy

View resources
Last reviewed: 27/04/20 by Nikhil Tanna

Checkmate 384: phase 3b/4 trial of Nivolumab 480 mg Q4W vs 240 mg Q2W after ≤12 months of Nivolumab in previously treated advanced NSCLC

View resources
Last reviewed: 27/04/20 by Paulina Billings

Analysis of the systemic anti-cancer therapy (SACT) returns pathway in chemotherapy preparation and dispensing unit (CPDU) to reduce waste and optimise efficiency

View resources
Last reviewed: 12/10/20 by Xabier Antón Méndez

Analysis of the effectiveness of a chemotherapy extravasation protocol in a tertiary care hospital

Abstracts

View resources
Last reviewed: 27/04/20 by Hasan Kobat

An evaluation of genetic markers for cardiotoxicity following doxorubicin chemotherapy

View resources
Last reviewed: 17/03/21 by Claire Baldwin

Advanced cancer pharmacy technician training and competency framework to validate simple repeat systemic anti-cancer treatment (SACT) prescriptions

Abstracts

View resources
Last reviewed: 27/04/20 by Anne O’Connor

Accuracy of carboplatin dosing in patients with gynaecological cancers

View resources
Last reviewed: 27/04/20 by Helma B. Oskarsdottir

A review of immune checkpoint inhibitor therapy in Iceland: indications and tolerability

View resources
Last reviewed: 12/10/20 by Man Hin Chu

A retrospective study on the clinical impact of gastric acid suppressants on the use of tyrosine kinase inhibitors in non-small cell lung cancer

Abstracts

View resources

Filter for resources

  • Types

  • Tags

  • Reset

1 2 3 Next
BOPA logo
  • Why join BOPA
  • Pricing/Join
  • Conference 2024
  • Education
  • About
  • News & Events
  • Help
  • Go to LinkedIn
  • Go to Twitter
  • Go to Facebook
  • Go to Instagram
  • Go to Bluesky

© Copyright 2025 British Oncology Pharmacy Association.
Registered Charity No. 1065026

  • Privacy Policy
  • T&Cs Website
  • T&Cs Membership
  • Cookies
  • Contact
Designed and developed by Rouge
Our website uses cookies to distinguish you from other users of our website. This helps us to provide you with a good experience when you browse our website and also allows us to improve our site. By continuing to browse the site, you are agreeing to our use of cookies.